US2017247253A1PendingUtilityA1
Nanoparticles for Use in Medical and Research Applications
Est. expiryMar 24, 2030(~3.7 yrs left)· nominal 20-yr term from priority
Inventors:Gretchen M. Unger
B82Y 5/00A61K 2039/55505A61K 31/713A61K 9/5115A61K 9/5123A61K 9/5161A61K 2039/55555
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications.
Claims
exact text as granted — not AI-modified1 . A method of treating a disease or disorder, comprising administering to a subject in need of such treatment, a therapeutically effective amount of non-viral nanoparticles, wherein said nanoparticles comprise a micelle core comprising a bioactive macromolecule and a surfactant with an HLB value of less than or equal to about 6.0, a shell adsorbed to the micelle core and comprising a ligand and lithium, and having a mean diameter of less than about 50 nanometers, wherein;
(a) the bioactive macromolecule comprises an oligonucleotide, a protein, a peptide, a carbohydrate, or an antibody; (b) the ligand comprises a protein, a peptide, a carbohydrate, an antibody, or a small molecule; and (c) the nanoparticles are administered subcutaneously.
2 . A pharmaceutical composition comprising non-viral nanoparticles comprising a micelle core comprising an antigen and a surfactant with an HLB value of less than or equal to about 6.0, a shell adsorbed to the micelle core and comprising a ligand, lithium, and an adjuvant, and having a mean diameter of less than about 50 nanometers, wherein;
(a) the antigen is hydrophilic and comprises a DNA plasmid, a protein, or a peptide; (b) the adjuvant comprises nickel; and (c) the ligand comprises hyaluronan, wherein said hyaluronan ligand has an average molecular weight of less than about 50,000 Daltons and is non-covalently attached to the nanoparticles.
3 . A method of inducing an immune response in a subject, comprising administering to the subject a therapeutically effective amount of the composition of claim 2 , wherein the composition is topically administered.
4 . A composition for imaging a subject, said composition comprising non-viral nanoparticles comprising a micelle core comprising an imaging agent, wherein the imaging agent is dysprosium, and a surfactant with an HLB value of less than or equal to about 6.0, a shell adsorbed to the micelle core and comprising a ligand and lithium, and having a mean diameter of less than about 50 nanometers.Join the waitlist — get patent alerts
Track US2017247253A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.